GlassScriptPhysician profile
Fereidoon Rafii
NPI 1417045402
$2,390.12
in general payments reported to CMS, 2019-2025
17 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2021: $122 · 2022: $547 · 2023: $635 · 2024: $275 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $557.71 | 2022-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $257.47 | 2019 | |
| Corcept Therapeutics | $202.57 | 2025 | Korlym |
| Althera Pharmaceuticals LLC | $153.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $135.00 | 2023 | Austedo |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Amgen INC. | $125.00 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.94 | 2023 | Cycloset |
| Vifor Pharma, INC. | $121.95 | 2019 | |
| Optinose US, INC. | $121.53 | 2021 | |
| Intuity Medical INC | $111.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $35.57 | 2019 | |
| Merck Sharp & Dohme LLC | $32.19 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.59 | 2019 | |
| Pfizer INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fereidoon Rafii listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.